EUVIMEDEUVIMED entdecken
Crossref

PRO: Patients With Recurrent Ovarian Cancer Should be Treated With Antiangiogenic Agents in Combination With Chemotherapy

David Boruta, John Farley, Michael J. Birrer

Clinical Ovarian Cancer · 2011

DOI: 10.1016/j.cloc.2012.02.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Ovarian Cancer, 2011. Verfasst von David Boruta und 2 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Boruta, D., Farley, J., & Birrer, M. J. (2011). PRO: Patients With Recurrent Ovarian Cancer Should be Treated With Antiangiogenic Agents in Combination With Chemotherapy. Clinical Ovarian Cancer. https://doi.org/10.1016/j.cloc.2012.02.008

Vancouver

Boruta D, Farley J, Birrer MJ. PRO: Patients With Recurrent Ovarian Cancer Should be Treated With Antiangiogenic Agents in Combination With Chemotherapy. Clinical Ovarian Cancer. 2011. doi:10.1016/j.cloc.2012.02.008

BibTeX
@article{Boruta2011,
  author = {Boruta, David and Farley, John and Birrer, Michael J.},
  title = {PRO: Patients With Recurrent Ovarian Cancer Should be Treated With Antiangiogenic Agents in Combination With Chemotherapy},
  journal = {Clinical Ovarian Cancer},
  year = {2011},
  doi = {10.1016/j.cloc.2012.02.008}
}
Kostenlos starten →